Compounds > imrecoxib
Page last updated: 2024-11-12

imrecoxib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Imrecoxib: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11682175
CHEMBL ID504535
SCHEMBL ID3034253
MeSH IDM0471735

Synonyms (19)

Synonym
imrecoxib
CHEMBL504535 ,
bap-909
bdbm50293282
SCHEMBL3034253
2h-pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-
SGW6W5758V ,
395683-14-4
unii-sgw6w5758v
imrecoxib [who-dd]
DB12354
AKOS032954049
4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1h-pyrrol-2(5h)-one
HY-114200
CS-0079499
Q27289202
4-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-1-propyl-2h-pyrrol-5-one
F82319
MS-25939

Research Excerpts

Overview

Imrecoxib is a novel and moderately selective cyclooxygenase-2 inhibitor with properties of anti-inflammation and alleviating pain, which is widely applied in osteoarthritis patients. It exhibits a good efficacy and tolerance in orthopedic disorders.

ExcerptReferenceRelevance
"Imrecoxib is a novel cyclooxygenase-2 inhibitor independently developed in China, which exhibits a good efficacy and tolerance in orthopedic disorders. "( Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study.
Guo, W; Li, J; Liu, Y, 2022)		3.61
"Imrecoxib is a selective COX-2 inhibitor developed independently in China."( A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
Chen, KM; Chu, YR; Tong, WQ; Wang, C; Wang, JX; Wang, XL; Xu, SQ; Zong, HX, 2022)		1.72
"Imrecoxib is a novel and moderately selective cyclooxygenase-2 inhibitor with properties of anti-inflammation and alleviating pain, which is widely applied in osteoarthritis patients. "( Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects.
Hu, C; Luo, Z; Shen, Q; Shu, S; Wang, Y; Yang, L; Zhu, X, 2022)		2.43
"Imrecoxib is a registered treatment for osteoarthritis pain symptoms in China. "( Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Huang, X; Li, Z; Liu, Y; Shi, S; Yang, C; Yang, T; Zhang, R; Zhang, Y; Zhou, J, 2019)		2.29
"Imrecoxib is a new moderately selective cyclooxygenase-2 (COX-2) inhibitor. "( Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation.
Huang, J; Li, Y; Pei, Q; Tan, H; Wang, J; Wang, Y; Yang, G; Yu, J; Zhang, H, 2020)		2.32
"Imrecoxib is a typical cyclooxygenase-2 inhibitor and the benzylic carbon motif is its major site of oxidative metabolism, producing a hydroxymethyl metabolite (M1) and a carboxylic acid metabolite (M2). "( Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate.
Chen, X; Hou, X; Yu, S; Zhang, Y; Zhong, D; Zhou, J; Zhou, L, 2018)		2.17
"Imrecoxib is a specific inhibitor of cyclooxygenase-2. "( Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry.
Chen, X; Dai, X; Hou, X; Yang, Y; Zhang, Y; Zhong, D, 2019)		2.25
"Imrecoxib is a novel and moderately selective COX-2 inhibitor that possesses anti-inflammatory effect by inhibition of COX-2 mRNA expression."( Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.
Bai, AP; Bai, JY; Chen, XH; Cheng, GF; Guo, ZR; Shen, F, 2004)		3.21
"Imrecoxib is a novel and moderately selective COX-2 inhibitor. "( Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver microsomes.
Chu, FM; Gong, AS; Guo, ZR; Sun, YM; Xu, HY; Zhang, P; Zhong, DF, 2006)		2.04

Actions

ExcerptReferenceRelevance
"Imrecoxib was found to inhibit COX-1 and COX-2 with IC50 value of 115+/-28 nmol/L and 18+/-4 nmol/L, respectively. "( Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.
Bai, AP; Bai, JY; Chen, XH; Cheng, GF; Guo, ZR; Shen, F, 2004)		3.21

Toxicity

ExcerptReferenceRelevance
" Besides, the incidences of all adverse events were not different between imrecoxib and celecoxib groups (all P > 0."( Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.
Cui, S; Jiang, L; Liu, Z; Miao, X; Wang, Z; Zhang, K, 2023)		1.4

Pharmacokinetics

The pharmacokinetic data supporting imrecoxib's rational use in elderly population are not available. The purpose of this research was to evaluate the effects of fluconazole, which is known to inhibit CYP2C9, on imre Coxib's Pharmacokinetic parameters.

ExcerptReferenceRelevance
" The purpose of this research was to evaluate the effects of fluconazole, which is known to inhibit CYP2C9, on imrecoxib's pharmacokinetic (PK) parameters."( Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
Chen, XY; Gong, Y; Hou, XY; Peng, WX; Zhang, YF; Zhong, DF; Zhu, RH; Zuo, CZ, 2018)		0.94
" We have investigated the pharmacokinetic parameters of imrecoxib and its two main metabolites in individuals with osteoarthritis (OA) with normal renal function and renal insufficiency, respectively."( Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Huang, J; Li, W; Liu, WY; Pei, Q; Tan, HY; Wang, Y; Xie, JL; Yang, GP; Yang, XY; Zhang, H, 2019)		1.06
" The pharmacokinetic data supporting imrecoxib's rational use in elderly population are not available."( Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects.
Hu, C; Luo, Z; Shen, Q; Shu, S; Wang, Y; Yang, L; Zhu, X, 2022)		1.26

Compound-Compound Interactions

Imrecoxib combined with lobaphatin has inhibitory effects on the growth of non-small cell lung cancer xenografts and lymph node metastasis via down-regulated ezrin and upregulated E-cadherin.

ExcerptReferenceRelevance
"To evaluate the inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung adenocarcinoma xenografts in nude mice, and to explore its possible mechanisms."( [Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF, 2016)		1.02
" Twenty-eight healthy male nude mice were randomly divided into 4 groups: the control group, imrecoxib group, lobaplatin group and imrecoxib combined with lobaplatin group."( [Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF, 2016)		0.97
"Administration of imrecoxib combined with lobaphatin has inhibitory effects on the growth of non-small cell lung cancer xenografts and lymph node metastasis via down-regulated ezrin and upregulated E-cadherin."( [Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF, 2016)		1.08

Dosage Studied

The dosage of imrecoxib should be reduced appropriately in patients with renal insufficiency.

ExcerptRelevanceReference
"43] years) received the following 2 treatments separated by a washout period of 8 days under a fasting state: (1) a single oral dose of imrecoxib 100 mg; and (2) fluconazole 200 mg/d over 6 days followed by concurrent dosing of imrecoxib 100 mg and fluconazole 200 mg."( Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
Chen, XY; Gong, Y; Hou, XY; Peng, WX; Zhang, YF; Zhong, DF; Zhu, RH; Zuo, CZ, 2018)		0.93
" These results indicate that the dosage of imrecoxib should be reduced appropriately in patients with renal insufficiency."( Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Huang, J; Li, W; Liu, WY; Pei, Q; Tan, HY; Wang, Y; Xie, JL; Yang, GP; Yang, XY; Zhang, H, 2019)		1.08
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1Mus musculus (house mouse)IC50 (µMol)0.11500.00072.08445.1000AID1130031; AID353232
Prostaglandin G/H synthase 2Mus musculus (house mouse)IC50 (µMol)0.01800.00050.40086.2000AID1130032; AID353233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID353234Selectivity index, ratio of IC50 for COX1 to IC50 for COX2 in mouse peritoneal macrophages2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
AID353527Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 1 hr relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
AID353530Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 4 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
AID353232Inhibition of COX1 in mouse peritoneal macrophages2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
AID353233Inhibition of COX2 in mouse peritoneal macrophages2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
AID353528Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 2 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
AID1130031Inhibition of calcimycin-induced COX-1 in peritoneal macrophage of C57BL/J6 mouse assessed as 6-Keto prostaglandin F1alpha formation preincubated for 1 hr followed by calcimycin challenge by radioimmunoassay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Synthetic approaches to the 2012 new drugs.
AID1130032Inhibition of LPS-induced COX-2 in peritoneal macrophage of C57BL/J6 mouse assessed as prostaglandin E2 formation preincubated for 1 hr followed by LPS challenge by radioimmunoassay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Synthetic approaches to the 2012 new drugs.
AID353529Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 3 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (25.00)29.6817
2010's8 (33.33)24.3611
2020's10 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.44 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index45.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (25.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (70.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		5.7863organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		7.1710conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		2.0310dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		3.811ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		7.03204pyrrole;
secondary amine
nadp
[no description available]		2.0310
quinine
[no description available]		2.0310cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		8.5911benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Anasarca
[description not available]		02.4420
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.4420
Acute Post-operative Pain
[description not available]		05.5233
Pain, Postoperative
Pain during the period after surgery.		05.5233
Pyogenic Sacroiliitis
[description not available]		02.610
Innate Inflammatory Response
[description not available]		04.0421
Arthritis, Spinal
[description not available]		04.0421
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		09.0421
Coxarthrosis
[description not available]		03.9911
Osteoarthritis, Hip
Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.		03.9911
Osteoarthritis of Knee
[description not available]		03.9911
Injuries, Knee
[description not available]		03.9911
Knee Injuries
Injuries to the knee or the knee joint.		03.9911
Osteoarthritis, Knee
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)		03.9911
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		04.5441
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		04.5441
Liver Dysfunction
[description not available]		02.2110
Liver Diseases
Pathological processes of the LIVER.		02.2110
Arthritis, Degenerative
[description not available]		03.5911
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		15.5911
Adenocarcinoma, Basal Cell
[description not available]		02.1310
Carcinoma, Non-Small Cell Lung
[description not available]		02.1310
Cancer of Lung
[description not available]		02.1310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.1310
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.1310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1310
Adjuvant Arthritis
[description not available]		02.0210